Dealmaking

AstraZeneca to buy PE-backed Amolyt Pharma for $1.05bn

Amolyt Pharma is a global clinical-stage biopharmaceutical company.

BlackRock's Nathalie von Niederhaeusern: Percentage of female investors needs to grow

'Private equity firms need to be focused not to lose talent in the development phase.'

EQT agrees to sell 20% stake in Ottobock

Ottobock is a med-tech company that provides wearable human bionics.

On the block: Freight, transport and logistics companies testing the market

CVC Capital Partners and Providence Equity Partners are among the PE sponsors testing the market this month for portfolio companies in the transportation market.

Apollo to exit 28.4% stake in Vallourec for €955m

Vallourec is a premium tubular steel products manufacturer.

Thoma Bravo returned billions to LPs in tough exit market; Advent on the growth of Sovos

Advent discusses its exit of Sovos Brands for $2.7 billion to Campbell Soup Co.

Estancia Capital Partners pumps €126m into Flagstone

Flagstone is a fintech company based in London.

GCP-backed Bridewell bolsters public sector footprint with Arculus deal

Arculus is a cyber security consultancy.

Eurazeo in healthcare exit

EQT, CVC cosmetics firms set IPO ranges; PAI launches women’s network.

Eurazeo to sell 100% of Peters Surgical’ share capital to Advanced Medical Solutions

Peters Surgical provides surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.